Correlation between Hearing Loss and Peritonitis Frequency and Administration of Ototoxic Intraperitoneal Antibiotics in Patients with CAPD

Figures & data

Table 1  Categorization of hearing functions

Hearing functions	Hearing loss range (dB)
Normal	−10 to 45
Slight-mild hearing loss	16 to 40
Moderate hearing loss	41 to 55
Severe hearing loss	56 to 90
Profound hearing loss	91+

* Adapted from reference 18.

Table 2  Demographic, biochemical, clinical, and audiometric parameters between patient groups with and without a history of peritonitis

Parameters	Peritonitis group (n = 64)	Control group (n = 42)	p
Age (year)	50.93 ± 13.95	48.47 ± 13.72	0.646
Gender			0.544
Male	36 (56.3%)	24 (57.1%)
Female	28 (43.7%)	18 (42.9%)
Causes of ESRD			0.677
Diabetic nephropathy	17 (26.6%)	13 (31%)
Hypertension	15 (23.4%)	13 (31%)
Glomerulonephritis	3 (4.7%)	1(2.4%)
Polycystic kidney disease	1 (1.6%)	2 (4.8%)
Amyloidosis	3 (4.7%)	1 (2.4%)
Others/unknown	25 (39.1%)	12 (28.6%)
Duration of CAPD (month)	36.16 ± 11.14	23.90 ± 6.76	0.001
Residual urine volume (mL)	150 (0–1500)	500 (0–2500)	0.001
Kt/Vurea	2 (1.15–6.50)	2.2 (1.55–6.00)	0.018
Value of PTA-1	30.50 (11–103)	17.50 (11–54)	0.001
Value of PTA-2	71.17 ± 20.99	33.59 ± 14.27	0.007
Ototoxicity-related symptoms
Presence of dizziness	21 (32.8%)	—	0.001
Presence of tinnitus	22 (34.4%)	—	0.001
Presence of instability	12 (18.8%)	—	0.001

*Abbreviations: ESRD = end-stage renal disease, CAPD = continuous ambulatory peritoneal dialysis, PTA = pure-tone average

Table 3  Assessment of hearing impairment according to values of PTA-1 and 2

		Normal	Mild	Moderate	Severe	Profound	p value
PTA-1
Peritonitis group (n = 64)		23 (35.9%)	33 (51.6%)	4 (6.3%)	4 (6.3%)	—	0.001
Control group (n = 42)		32 (76.2%)	10 (23.8%)	—	—	—
PTA-2
Peritonitis group (n = 64)		—	15 (23.4%)	15 (23.4%)	32(50%)	2 (3.1%)	0.001
Control group (n = 42)		16 (38.1%)	22 (52.4%)	4 (9.5%)	—	—

*p values when compared with the controls.

Figure 1.  Correlation between threshold hearing levels and usages of the increased doses of intraperitoneal cephalozine, vancomycin, and amikacin in CAPD peritonitis therapy.